Nkarta, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NKTX research report →
Range $9 – $9
Price Chart
About the company
Nkarta, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
- CEO
- Paul J. Hastings
- IPO
- 2020
- Employees
- 103
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on NKTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $81.29M
- P/E
- -0.72
- PEG
- 0.03
- P/S
- 0.00
- P/B
- 0.43
- EV/EBITDA
- -0.93
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -48.58%
- ROIC
- -48.89%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-9,193,000+0.0%
- Op Income
- $-121,206,000
- Net Income
- $-104,084,000+4.3%
- EPS
- $-1.41+11.9%
- OCF Growth
- +11.0%
- FCF Growth
- +13.6%
- 52W High
- $3.72
- 52W Low
- $1.10
- 50D MA
- $2.06
- 200D MA
- $2.47
- Beta
- 0.97
- RSI (14)
- 30
- Avg Volume
- 1.01M
No earnings-call transcripts are available for NKTX yet.
- Free Float
- 80.5%
- Shares Outstanding
- 71.62M
- Float Shares
- 57.63M
of shares held by institutions
141 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 10.81M | 0 |
| Blackrock, Inc. | 6.85M | ▲ 547.00K |
| Nea Management Company, LLC | 3.57M | 0 |
| Samsara Biocapital, LLC | 3.51M | 0 |
| Sr One Capital Management, LP | 3.33M | 0 |
| Gsk PLC | 3.15M | 0 |
| Vanguard Group Inc | 2.60M | ▲ 105.65K |
| Vanguard Capital Management LLC | 2.36M | ▲ 136.99K |
| Monaco Asset Management Sam | 2.19M | ▼ 187.73K |
| Citadel Advisors LLC | 2.17M | ▲ 390.75K |
| Two Sigma Investments, LP | 1.87M | ▼ 174.08K |
| Acadian Asset Management LLC | 1.73M | ▲ 368.20K |
Held by 120 ETFs
Biggest fund positions in NKTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | HASTINGS PAUL J | sell | 1,776 |
| Jun 10, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 37,000 |
| Jun 10, 26 | Behbahani Ali | other | 37,000 |
| Jun 10, 26 | George Simeon | other | 37,000 |
| Jun 10, 26 | Vratsanos George | other | 37,000 |
| Jun 10, 26 | Scheiner Zachary | other | 37,000 |
| Jun 10, 26 | PATTERSON LEONE D | other | 37,000 |
| Jun 10, 26 | Dybbs Michael | other | 37,000 |
| Jun 10, 26 | Thedinga Angela | other | 37,000 |
| Jan 15, 26 | HASTINGS PAUL J | sell | 26,046 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NKTX coverage
Recent articles, reports, and earnings notes.
No research on NKTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NKTX report →Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
globenewswire.com · Nov 11
Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis Transcript
seekingalpha.com · Nov 9
Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence
globenewswire.com · Nov 9
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
globenewswire.com · Nov 6
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 5
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
defenseworld.net · Sep 28
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
marketbeat.com · Sep 27
Nkarta (NASDAQ:NKTX) Stock Falls 3.5% – Here’s Why
defenseworld.net · Sep 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.